Table 1:

Summary of recurrent YAP1 and TAZ fusions identified in human cancers.

Fusion	Tumor type	Retained YAP1/TAZ amino acids	Retained C-terminal fusion partner amino acids	References
YAP1-FAM118B	ST-Ependymoma; NF2-wild type Meningioma	aa1-aa388 (exons 1–7)	aa1-aa351 (entire sequence)	(Pajtler et al. 2015; Schieffer et al. 2020)
YAP1-KMT2A	Sclerosing Epithelioid Fibrosarcoma; Fibromyxoid Sarcoma	1) aa1-aa267 (exons 1–4) 2) aa1-aa328 (exons 1–5)	1) aa1112-aa3969 (exons 5–36) 2) aa1053-aa3969 (exons 4–36)	(Kao et al. 2020; Puls et al. 2020)
YAP1-LMO1	NF2-wild type Meningioma	aa1-aa267(exons 1–4)	aa9-aa156 (exons 2–4)	(Sievers et al. 2020)
YAP1-MAMLD1	ST-Ependymoma	1) aa1-aa328 (exons 1–5) 2) aa1-aa344 (exons 1–6)	1) aa58-aa774 (exons 3–7) 2) aa33-aa774 (exons 2–7)	(Pajtler et al. 2015)
YAP1-MAML2	Head and Neck Carcinoma; Nasopharyngeal Carcinomas; NF2-wild type Meningioma; Ovarian Carcinoma; Poroma/Porocarcinoma; Retiform and Composite Hemangioendothelioma	1) aa1-aa107 (exon 1) 2) aa1-aa328 (exons 1–5)	1) aa172-aa1152 (exons 2–5) 2) aa172-aa1152 (exons 2–5)	(Picco et al. 2019; Sekine et al. 2019; Antonescu et al. 2020; Sievers et al. 2020)
YAP1-NUTM1	Poroma/Porocarcinoma	1) aa1-aa229 (exons 1–3) 2) aa1-aa267 (exons 1–4)	1) aa6-aa1132 (exons 2–7) 2) aa6-aa1132 (exons 2–7)	(Sekine et al. 2019)
YAP1-PYGO1	NF2-wild type Meningioma	aa1-aa267(exons 1–4)	aa17-aa419(exons 2–3)	(Sievers et al. 2020)
YAP1-SS18	Cervical Squamous Cell Carcinoma; Endocervical Adenocarcinoma	aa1-aa107 (exon 1)	aa1-aa418 (entire sequence)	(Szulzewsky et al. 2020)
YAP1-TFE3	Epithelioid Hemangioendothelioma	aa1-aa107 (exon 1)	aa179-aa575 (exons 4–10)	(Antonescu et al. 2013)
TAZ-CAMTA1	Epithelioid Hemangioendothelioma	1) exons 1–2 2) exons 1–4	1) exons 9–23 2) exons 8/9–23	(Errani et al. 2011; Tanas et al. 2011)